Table 1.
DMTs for MS included in the retrospective claims database analysisa
| Route | DMT | Manufacturer | Dosing frequency | Approval year (US) |
|---|---|---|---|---|
| Injectable | Avonex® (IFNβ-1a) | Biogen | Once weekly | 1996 |
| Betaseron® (IFNβ-1b) | Bayer Healthcare Pharmaceuticals | Every other day | 1993 | |
| Copaxone® (glatiramer acetate 20/40 mg) | Teva Pharmaceuticals | Daily/3 times weekly | 1996/2014 | |
| Extavia® (IFNβ-1b) | Novartis Pharmaceuticals | Every other day | 2009 | |
| Rebif® (IFNβ-1a) | EMD Serono | 3 times weekly | 2002 | |
| Tysabri® (natalizumab) | Biogen | Once every 4 weeks | 2004 | |
| Oral | Aubagio® (teriflunomide) | Genzyme | Once daily | 2012 |
| Gilenya® (fingolimod) | Novartis Pharmaceuticals | Once daily | 2010 | |
| Tecfidera® (dimethyl fumarate) | Biogen | Twice daily | 2013 |
Note:
a
More recently approved DMTs – including Zinbryta® (daclizumab), once-weekly injectable; Glatopa® (glatiramer acetate 20 mg), once-daily injectable; Lemtrada® (alemtuzumab) daily infusion on five consecutive days the first year and on three consecutive days one year apart from first year and PLEGRIDY® (PEG-IFNβ-1a), injectable every 14 days – were not included, due to insufficient claims data at the end of the study period (September 30, 2015).
Abbreviations: DMTs, disease-modifying therapies; MS, multiple sclerosis.